Veeco Instruments Inc. — Q3 2023 Form 10-Q
Business context and period: Veeco develops, manufactures, sells, and supports semiconductor and thin-film process equipment. It reports one operating segment and serves Semiconductor, Compound Semiconductor, Data Storage, and Scientific & Other markets. This unaudited quarterly report covers the period reported as ended September 30, 2023, with comparisons to the prior-year quarter and nine-month period. Dollar amounts below are in millions unless noted.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $177.4 | $171.9 | $492.5 | $492.3 |
| Gross profit / margin | $76.9 / 43.3% | $70.0 / 40.7% | $206.4 / 41.9% | $200.2 / 40.7% |
| Operating income / margin | $22.3 / 12.5% | $17.6 / 10.2% | $45.8 / 9.3% | $46.9 / 9.5% |
| Net income (loss) | $24.6 | $15.0 | $(52.0) | $38.0 |
| Diluted EPS | $0.42 | $0.27 | $(0.98) | $0.70 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $32.2 | $75.4 |
- Q3 sales increased 3% year over year. Data Storage and Scientific & Other grew 23% and 25%, respectively; Semiconductor declined 2% and Compound Semiconductor declined 9%.
- Nine-month sales were essentially flat. Semiconductor sales rose 8% and Scientific & Other 10%, offset by a 26% decline in Compound Semiconductor and a 2% decline in Data Storage.
- Q3 gross margin improved, which management attributed to product mix and favorable spending. Nine-month operating income declined slightly as operating expenses grew faster than gross profit.
- The nine-month net loss included a $97.1 million non-cash loss on extinguishment of convertible debt ($16.5 million on the 2025 Notes and $80.6 million on the 2027 Notes). The filing reports no comparable charge in 2022.
- Nine-month operating cash flow fell to $32.2 million, with cash absorbed mainly by higher inventory, contract assets, and prepaid expenses. Inventory was $252.1 million at September 30, up from $206.9 million at year-end 2022.
Liquidity, debt, and commitments
- Cash, restricted cash, and short-term investments totaled $286.9 million at September 30, 2023, versus $303.0 million at December 31, 2022.
- Convertible notes had $281.5 million principal outstanding and $274.6 million net carrying value. The $230 million 2029 Notes were issued in May; proceeds funded partial repurchases of the 2025 and 2027 Notes and general corporate purposes. No borrowings were outstanding under the $150 million revolving credit facility.
- Management said projected operating cash flow and available cash and investments should cover working capital, contractual obligations, and other cash needs for the next 12 months. The company also stated it had no immediate plans to draw on the facility.
- Purchase commitments totaled $216.2 million, substantially all due within one year. Remaining performance obligations on contracts with original durations over one year were $244.5 million; about 83% was expected to be recognized within one year.
Outlook, commentary, and risks
- Management forecast 2023 revenue of $648 million to $668 million and expected Semiconductor revenue to grow about 10% for the year. It also expected Data Storage revenue growth in 2023, and initial revenue from the acquired SiC technology in 2024.
- Management cited macroeconomic uncertainty, softer demand in some applications, low customer utilization, and customer requests to cancel orders, delay shipments, or defer payments. It is managing expenses while continuing investment in growth areas.
- Supply-chain conditions were improving, including lead times and supplier delivery performance, but some material lead times remained above pre-pandemic levels. Veeco had increased purchase commitments to secure critical components.
- Veeco said it did not then expect the October 2023 U.S. export-control update to have a material impact, but warned that further controls could restrict China sales and cause revenue loss. China represented 32% of nine-month sales, up from 20% in the prior-year period.
- The Epiluvac acquisition, completed January 31, 2023, had $56.4 million acquisition-date consideration, including $26.1 million estimated contingent consideration. The contingent liability was $24.7 million at September 30; its valuation depends on estimates and uncertain adoption of SiC technology.
- Other disclosed risks include industry cyclicality, concentrated customers and suppliers, order timing and cancellations, technology and competitive pressures, export licensing, foreign currency exposure, and potential inventory obsolescence. The company said ordinary-course legal proceedings were not expected to have a material adverse effect.
Important facts for investors to verify
- How actual Q4 sales compare with the $648 million–$668 million full-year revenue outlook, given that nine-month sales were $492.5 million and management described continuing demand uncertainty.
- Whether inventory growth, purchase commitments, and customer order changes convert into shipments and cash generation without material write-downs or delays.
- The extent to which China export controls or shifts in regional demand affect revenue, given China’s increased share of nine-month sales.
- The timing and eventual value of Epiluvac contingent payments, and whether expected SiC market adoption supports the acquisition’s growth rationale.
- The filing contains inconsistent statements about the 2027 Notes’ conversion eligibility: the debt note gives a different timing description from the later MD&A discussion. Verify the applicable conversion window and related dilution implications.